Conditions: Gastrointestinal Stromal Tumors Soft Tissue Sarcomas
Keywords: cancer tumour advanced cancer Metastatic Gastro-Intestinal Stromal Tumours gastro-intestinal cancer RECENTIN
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 35
Healthy volunteers: no

Brief summary:
To determine the anti-tumour activity and biological effects of cediranib (AZD2171) at a dose of 45mg, primarily in Gastrointestinal Stromal Tumour (GIST) patients who are resistant to imatinib mesylate (current standard therapy) and also in patients with metastatic Soft Tissue Sarcoma (STS) resistant to standard therapy.

Detailed description:

Arms:

Interventions: intervention 1: AZD2171
Intervention descriptions: intervention 1: 45 mg oral tablet once daily dose

Protocol document: